EUCTR2018-001271-20-IT进行中（未招募）1 期
A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 With A Partially Blinded Extension Period To Evaluate The Efficacy And Safety Of Pf06651600 And Pf-06700841 In Subjects With Active Non-Segmental Vitiligo -
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- PFIZER INC
- 入组人数
- 660
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female subjects between 18-65 years of age, inclusive, at time of informed consent.
- •Must have moderate to severe active non-segmental vitiligo.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 660
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •History of human immunodeficiency virus (HIV) or positive HIV serology at screening.
- •Infected with hepatitis B or hepatitis C viruses.
- •Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB).
研究者
相似试验
已完成
2 期
A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitisonalcoholic SteatohepatitisJPRN-jRCT2051200083Tanaka Yoshiyuki328
进行中（未招募）
1 期
Phase 2b Study of MK-3655 in Individuals with Pre cirrhotic Nonalcoholic Steatohepatitis (NASH)MedDRA version: 24.1Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2019-003048-63-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.328
进行中（未招募）
1 期
Phase 2b Study of MK-3655 in Individuals with Pre cirrhotic Nonalcoholic Steatohepatitis (NASH)MedDRA version: 22.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2019-003048-63-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.328
招募中
2 期
Phase 2b Study of Efinopegdutide (MK-6024) in Adults with Precirrhotic Nonalcoholic SteatohepatitisK758 Other specified inflammatory liver diseasesOther specified inflammatory liver diseasesK758PER-024-23Merck Sharp & Dohme LLC., (una subsidiaria de Merck & Co. Inc.)
招募中
2 期
Phase 2b Study of Efinopegdutide (MK-6024) in Adults with Precirrhotic Nonalcoholic SteatohepatitisJPRN-jRCT2031230187Tanaka Yoshiyuki30